Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wonkyung Byon

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|September 12, 2015
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixabanMing Chang, Zhigang Yu, Andrew Shenker, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2023
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorderSamira J Merali, Wonkyung Byon, Yogesh T Patel, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 1, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
Journal of Clinical Pharmacology|July 8, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
Clinical Pharmacology : Advances and Applications|May 3, 2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorVijay V Upreti, Yan Song, Jessie Wang, et al.
British Journal of Clinical Pharmacology|March 16, 2013
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjectsVijay V Upreti, Jessie Wang, Yu Chen Barrett, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 11, 2016
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor XaBlisse Vakkalagadda, Charles Frost, Wonkyung Byon, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixabanCharles Frost, Andrew Shenker, Mohit D Gandhi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 15, 2022
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study DataMichael J Jamieson, Wonkyung Byon, Richard W Dettloff, et al.
British Journal of Clinical Pharmacology|March 5, 2013
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjectsCharles Frost, Sunil Nepal, Jessie Wang, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|September 12, 2015
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixabanMing Chang, Zhigang Yu, Andrew Shenker, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 2, 2023
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorderSamira J Merali, Wonkyung Byon, Yogesh T Patel, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 1, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
Journal of Clinical Pharmacology|July 8, 2015
Reporting guidelines for population pharmacokinetic analysesKevin Dykstra, Nitin Mehrotra, Christoffer Wenzel Tornøe, et al.
Clinical Pharmacology : Advances and Applications|May 3, 2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorVijay V Upreti, Yan Song, Jessie Wang, et al.
British Journal of Clinical Pharmacology|March 16, 2013
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjectsVijay V Upreti, Jessie Wang, Yu Chen Barrett, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 11, 2016
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor XaBlisse Vakkalagadda, Charles Frost, Wonkyung Byon, et al.
British Journal of Clinical Pharmacology|April 5, 2014
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixabanCharles Frost, Andrew Shenker, Mohit D Gandhi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 15, 2022
Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study DataMichael J Jamieson, Wonkyung Byon, Richard W Dettloff, et al.
British Journal of Clinical Pharmacology|March 5, 2013
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjectsCharles Frost, Sunil Nepal, Jessie Wang, et al.
Pageof 3